FI990171A - Novel compounds and compositions for the treatment of diseases related to tryptase activity - Google Patents

Novel compounds and compositions for the treatment of diseases related to tryptase activity Download PDF

Info

Publication number
FI990171A
FI990171A FI990171A FI990171A FI990171A FI 990171 A FI990171 A FI 990171A FI 990171 A FI990171 A FI 990171A FI 990171 A FI990171 A FI 990171A FI 990171 A FI990171 A FI 990171A
Authority
FI
Finland
Prior art keywords
compositions
treatment
novel compounds
diseases related
tryptase activity
Prior art date
Application number
FI990171A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI990171A0 (en
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Ric
Vivian Rueywen Wang
Wendy Beth Young
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of FI990171A0 publication Critical patent/FI990171A0/en
Publication of FI990171A publication Critical patent/FI990171A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI990171A 1996-07-30 1999-01-29 Novel compounds and compositions for the treatment of diseases related to tryptase activity FI990171A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (2)

Publication Number Publication Date
FI990171A0 FI990171A0 (en) 1999-01-29
FI990171A true FI990171A (en) 1999-03-23

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
FI990171A FI990171A (en) 1996-07-30 1999-01-29 Novel compounds and compositions for the treatment of diseases related to tryptase activity

Country Status (17)

Country Link
EP (1) EP0934293A1 (en)
JP (1) JP2001509787A (en)
KR (1) KR20000029679A (en)
CN (1) CN1073103C (en)
AU (1) AU733621B2 (en)
CA (1) CA2262542A1 (en)
CZ (1) CZ29799A3 (en)
EE (1) EE9900036A (en)
FI (1) FI990171A (en)
HU (1) HUP0003267A3 (en)
LV (1) LV12291B (en)
NO (1) NO990433L (en)
NZ (1) NZ333713A (en)
PL (1) PL331465A1 (en)
SI (1) SI9720047A (en)
SK (1) SK8599A3 (en)
WO (1) WO1998004537A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
JP2002502850A (en) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Tryptase inhibitor
AU2723099A (en) * 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
WO2000014097A2 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
US6673786B1 (en) 1999-08-10 2004-01-06 Altana Pharma Ag Tryptase inhibitors
JP2003509417A (en) * 1999-09-14 2003-03-11 アルタナ ファルマ アクチエンゲゼルシャフト Tryptase inhibitor
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (en) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments
US7015325B2 (en) * 1999-12-20 2006-03-21 Altana Pharma Ag Tryptase inhibitors
TR200402164T4 (en) 1999-12-20 2004-10-21 Altana Pharma Ag Tryptase inhibitors
CA2438594A1 (en) * 2001-01-31 2002-08-08 Altana Pharma Ag Diazocine derivatives and their use as tryptase inhibitors
WO2002066420A2 (en) * 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
CA2438685A1 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
EP1370518A2 (en) * 2001-03-15 2003-12-17 ALTANA Pharma AG Tryptase-inhibitors
KR20040016882A (en) 2001-06-11 2004-02-25 제노포트 인코포레이티드 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE348803T1 (en) 2001-06-19 2007-01-15 Altana Pharma Ag TRYPTASE INHIBITORS
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
CN102159201A (en) * 2008-12-19 2011-08-17 莫茨药物股份两合公司 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
TWI432188B (en) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
FR3038605B1 (en) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE
AU2018266393A1 (en) * 2017-05-12 2019-12-19 Riken Class A GPCR-binding compound modifier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
UA42719C2 (en) * 1993-03-12 2001-11-15 Аксіз Фармасьютікелз, Інк Compositions and methods for the treatment of immunomediated inflammatory disorders
JPH10501238A (en) * 1994-06-01 1998-02-03 アリス ファーマシューティカル コーポレイション Compositions and methods for treating mast cell mediated conditions
EP0782571A1 (en) * 1994-09-23 1997-07-09 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
JPH11503417A (en) * 1995-03-24 1999-03-26 アリス・ファーマシューティカル・コーポレイション Reversible protease inhibitor
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
LV12291B (en) 2000-04-20
KR20000029679A (en) 2000-05-25
FI990171A0 (en) 1999-01-29
CZ29799A3 (en) 1999-06-16
NZ333713A (en) 2000-12-22
CN1073103C (en) 2001-10-17
AU3967097A (en) 1998-02-20
PL331465A1 (en) 1999-07-19
NO990433L (en) 1999-03-25
AU733621B2 (en) 2001-05-17
CA2262542A1 (en) 1998-02-05
EE9900036A (en) 1999-08-16
EP0934293A1 (en) 1999-08-11
SK8599A3 (en) 2000-03-13
HUP0003267A2 (en) 2001-06-28
NO990433D0 (en) 1999-01-29
WO1998004537A1 (en) 1998-02-05
JP2001509787A (en) 2001-07-24
HUP0003267A3 (en) 2002-02-28
LV12291A (en) 1999-06-20
SI9720047A (en) 1999-08-31
CN1226892A (en) 1999-08-25

Similar Documents

Publication Publication Date Title
FI990171A (en) Novel compounds and compositions for the treatment of diseases related to tryptase activity
DE69509544T2 (en) COMPOSITION FOR THE TREATMENT OF OVARIAL OSTROGEN-DEPENDENT DISEASES
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
FI953180A0 (en) Compositions for the treatment of diabetic complications
DE69739583D1 (en) TOPICAL COMPOSITIONS CONTAIN AS A THERAPEUTICALLY ACTIVE AGENT A MONOGLYCERIDE FOR THE TREATMENT OF SLEW-TONE INFECTIONS
FI972387A (en) Parasiticidal compositions for application to the skin
DE69117117D1 (en) Cleaning composition for the prevention and alleviation of skin irritation
ATE262331T1 (en) HETEROCYCLIC VINYL ETHERS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE69812784D1 (en) Composition for the prevention and elimination of plant diseases
DE69841984D1 (en) COMPOSITION OF NANOCAPSULES FOR THE TREATMENT OF INTRAARTICULAR DISEASES
PL332430A1 (en) Skin care compositions containing combinations of compounds capable to simulate the action of retinic acid onto skin
EE04055B1 (en) Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity, and their use
DE69620691D1 (en) Therapeutic agent for the treatment of hypercholesterolemia
DE69405919T2 (en) Compositions for the treatment of keratin fibers
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
DE69807466D1 (en) TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
HUP0104963A3 (en) Compositions for the treatment of skin diseases
ID25765A (en) COMPOSITION OF SKIN CLEANER
DE69822297D1 (en) TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ID23175A (en) THE USE OF BENZOPIRANOL TO TREAT NERVE DISORDERS
DE69913380D1 (en) COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES
ID21369A (en) PHARMACEUTICAL COMPOSITION FOR HEALING OF DISEASES CAUSED BY VIRUS
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
NO982562D0 (en) Composition for the treatment of pain